Samsung Biologics

Samsung Biologics Co., Ltd.
Company typePublic
KRX: 207940
IndustryBiopharmaceuticals
Founded2011 (2011)
Headquarters
Songdo, Incheon
,
South Korea
Area served
Worldwide
Key people
John Rim (president and CEO)[1]
Revenue KRW 4.55 trillion (2024) [2]
KRW 325.7 billion (2024) [2]
Owners
Number of employees
5,300 (2025)
SubsidiariesSamsung Bioepis
Websitesamsungbiologics.com

Samsung Biologics Co., Ltd. (Korean: 삼성바이오로직스) is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines.

The company has partnered with pharmaceutical companies such as Pfizer,[3] GlaxoSmithKline,[4] Eli Lilly,[5] AstraZeneca[6] and Bristol-Myers Squibb.[7]

History

Facilities & Expansion

Founded in 2011,[8] Samsung Biologics built four manufacturing plants between 2011 and 2023 with a combined capacity of 605,000 liters.[9][10][11] In 2023, Samsung Biologics began construction of a fifth plant in Incheon, South Korea with a capacity of 180,000 liters. In March 2025, Samsung Biologics began operations at its dedicated antibody-drug conjugate (ADC) manufacturing facility in Songdo,[12] expanding its service capabilities into ADC production. With the addition of Plant 5, the company holds a total manufacturing capacity of 785,000 liters.

Since 2020, Samsung Biologics has expanded its United States operations, opening offices in New Jersey[13] and Boston[14] to more closely support U.S. biopharmaceutical companies across both coasts. In 2025, Samsung Biologics also opened a regional office in Tokyo[15], Japan, to strengthen ties with Japanese pharmaceutical and biotechnology companies. In 2025, Samsung acquired the Human Genome Sciences drug production facilities based in Rockville, Maryland from GSK plc for $280 million to establish their first US production site.[16]

In 2025, Samsung Biologics launched ExellenS™, a manufacturing framework based on the company's experience in plant design, digitalization, and operations. The framework standardizes equipment, processes, and functional specifications to facilitate technology transfers, regulatory approvals, and production outcomes. Samsung Biologics uses the ExellenS™ model to maintain consistency across its manufacturing operations.[17][18][19][20]

Notable Partnerships

As of June 2024, Samsung Biologics' CEO John Rim reported active partnerships with 16 of the top 20 largest biopharmaceutical companies.[21][22] This includes early deals with Roche[23] and Bristol-Myers Squibb[24] in 2013, through to large partnerships during and after the pandemic. In 2020, GSK and Samsung Biologics signed the first of two major agreements: a $231 million, eight-year deal to manufacture biological therapies, including the lupus drug Benlysta.[25] Two years later, a second $296 million deal was signed.[26]

During the COVID-19 pandemic, Samsung Biologics partnered with Moderna for fill-finish, packaging and labeling of its mRNA vaccine, Spikevax.[27][28] The company was also contracted to manufacture Eli Lilly's COVID-19 antibody therapeutic[29] and AstraZeneca's long-acting antibody therapeutic as part of a larger multi-product deal.[30]

In June 2023, Samsung Biologics entered a partnership with Pfizer for the commercial manufacturing of Pfizer’s multi-product biosimilars portfolio in a deal worth $411 million.[3] A month later, Samsung Biologics entered two deals with Pfizer worth a combined $897 million to produce biosimilar products ranging from oncology and inflammation to immunotherapy at its Plant 4.[31]

Along with Big pharma partnerships, the company has engaged with smaller development-stage companies. In 2023, Samsung Biologics announced a multi-year agreement with European venture capital firm Kurma Partners to support its portfolio companies through development, manufacturing, and de-risking services.[32] In February 2024, Samsung Biologics announced a partnership agreement with LigaChem (formerly LegoChem) Biosciences to provide antibody development and drug substance manufacturing services to support LigaChem's antibody-drug conjugate (ADC) pipeline.[33]

Samsung Biologics signed a 1.7 trillion won ($1.2 billion) deal with an unnamed Asian pharmaceutical company to provide contract manufacturing organization services, the largest contract secured in the company's history.[34]

Business Ventures

In 2012, it established Samsung Bioepis, a biosimilar medicine developer, as a joint venture with Biogen.[35] The company acquired full ownership of Samsung Bioepis in 2022 by purchasing all remaining shares from Biogen for $2.3 billion.[36] Samsung Biologics completed its spin-off of Samsung Bioepis.[37]

In 2021, the Samsung Life Science Fund was created through a joint partnership between Samsung Biologics, Samsung Bioepis, and Samsung C&T.[38] The fund, managed by Samsung Ventures, aims to foster the growth of next-generation technologies, such as gene therapies and ADCs.

Platforms

Samsung Biologics has developed a range of proprietary technologies for biologics development. This includes S-CHOice, a cell line expression technology introduced in 2020.[39] In 2022, Samsung Biologics launched S-DUAL, a bispecific antibody platform,[40] and its DEVELOPICK platform, a service that selects candidate materials for new drugs. Samsung Biologics has since expanded its technology portfolio with additional platforms, including S-CHOsient[41], S-AfuCHO[42], S-Tensify[43], S-Glyn[44], S-OptiCharge[45], and S-HiCon.[46]

Sustainability

Samsung Biologics published its first annual sustainability report in June 2021. It was added to the Dow Jones Sustainability World Index later that year.[47] The company was awarded the Sustainable Market Initiative's 2022 Terra Carta Seal, which recognizes global companies driving innovation and action towards the creation of genuinely sustainable markets.[48] In 2023, Samsung Biologics received both a leadership A− score from the Carbon Disclosure Project (CDP)[49] and an EcoVadis Gold Sustainability Rating.[50]

Samsung Biologics participates in several global sustainability and responsible-business initiatives, including the Sustainable Markets Initiative (SMI), the Pharmaceutical Supply Chain Initiative (PSCI), the Task Force on Climate-related Financial Disclosures (TCFD), RE100, the United Nations Global Compact (UNGC), Sustainalytics assessments, and EcoVadis.

Corporate governance

As of 30 June 2023.

Shareholder Stake (%) Flag
Samsung C&T 43.06%
Samsung Electronics 31.22%
National Pension Service 8.13%

See also

References

  1. ^ "Samsung Biologics names John Rim as new chief". The Korea Times. 17 December 2020.
  2. ^ a b "Samsung Biologics reports fourth quarter and fiscal year 2024 financial results".
  3. ^ a b biopharma-reporter.com (2023-06-12). "Samsung Biologics inks biosimilar manufacturing deal with Pfizer". biopharma-reporter.com. Retrieved 2023-06-14.
  4. ^ Dunleavy, Kevin (21 October 2022). "GSK and Samsung Bio double down with 2nd manufacturing deal, this one for $296M". Fierce Pharma. Retrieved 22 July 2024.
  5. ^ Sagonowsky, Eric (17 November 2020). "Lilly partners with Samsung to boost COVID-19 antibody manufacturing amid supply concerns". Fierce Pharma. Retrieved 22 July 2024.
  6. ^ Blankenship, Kyle (22 September 2020). "AstraZeneca, Samsung reach $331M biologics manufacturing deal amid Korean CMO's expansion push". Fierce Pharma. Retrieved 22 July 2024.
  7. ^ Lynch, Connor (18 September 2023). "Samsung Biologics Strikes $242M Manufacturing Deal with BMS for Cancer Antibody". BioSpace. Retrieved 22 July 2024.
  8. ^ "Blazing Samsung Biologics trail into new territory". The Korea Herald. 30 January 2020.
  9. ^ "Samsung BioLogics annual sales up 30% on contract research growth". Korea Biomedical Review. 23 January 2020.
  10. ^ "Samsung Biologics to add new contract drug-making plant". The Korea Times. 20 March 2020.
  11. ^ Manalac, Tristan (5 July 2023). "Pfizer Inks Manufacturing Deals with Samsung Biologics Worth Nearly $900M". www.biospace.com.
  12. ^ Choi, Mun-hee (2025-06-10). "Lee Jae-yong Visits State-of-the-art Samsung Biologics Plant No. 5".
  13. ^ Han-na, Park (6 June 2023). "[Bio USA] Samsung Biologics seeks giant leap with new plant, ADC tech". The Korea Herald.
  14. ^ Hae-yeon, Kim (2025-06-19). "[Bio USA] Samsung Biologics expands strategic focus to top 40 global pharma". The Korea Herald. Retrieved 2025-12-03.
  15. ^ "Samsung Biologics Expands Presence in Japan with New Tokyo Office". biopharmaapac.com. Retrieved 2025-12-03.
  16. ^ Kansteiner, Fraiser (22 December 2025). "Samsung Biologics pays GSK $280M to secure first US manufacturing site | Fierce Pharma". www.fiercepharma.com.
  17. ^ Korea’s Samsung Biologics Introduces Optimised Manufacturing Framework ExellenS – BioSpectrum Asia
  18. ^ Samsung Biologics Introduces Optimized Manufacturing Framework ExellenS – BioSpace
  19. ^ Samsung Biologics Launches ExellenS Framework to Standardize and Accelerate Biomanufacturing Operations – Global Pharma Update
  20. ^ Samsung Biologics Launches ExellenS Framework to Standardise and Accelerate Global Biomanufacturing – PR Newswire
  21. ^ Ha-Nee, Shin (7 June 2024). "Business soars for Korean pharma as U.S. cuts ties with Chinese partners". Korea JoongAny Daily.
  22. ^ Ahn, Dae-Kyu (7 June 2024). "Samsung Biologics eyes windfall gain amid US-China row". KED Global. The Korean Economic Daily.
  23. ^ Tyler, Dominic (24 October 2013). "Roche signs biologics partnership with Samsung". PMLiVE.
  24. ^ Thomas, Felicity (20 September 2023). "Samsung Biologics Expands Strategic Manufacturing Agreement with Bristol Myers Squibb". Pharmaceutical Technology.
  25. ^ Liu, Angus (22 May 2020). "GlaxoSmithKline hands Samsung Biologics $231M to scale up manufacturing". Fierce Pharma.
  26. ^ Dunleavy, Kevin (21 October 2022). "GSK and Samsung Bio double down with 2nd manufacturing deal, this one for $296M". Fierce Pharma.
  27. ^ "Moderna taps Samsung for fill-finish duties on 'hundreds of millions' of COVID-19 vaccine doses". Fierce Pharma. 24 May 2021.
  28. ^ "Samsung Biologics, GreenLight to produce COVID vaccine for Africa". The Korea Herald. 25 November 2021.
  29. ^ Stanton, Dan (23 November 2020). "Samsung Bio in $150m deal to make COVID antibodies for Lilly". BioProcess International.
  30. ^ Keenan, Joseph (14 December 2021). "Samsung Biologics, AstraZeneca expand manufacturing partnership to add COVID and cancer therapies". Fierce Pharma.
  31. ^ Yim, Hyunsu (4 July 2023). "Samsung Biologics unveils $897 million manufacturing deals for Pfizer". Reuters.
  32. ^ Nelson, Millie (30 October 2023). "Samsung Biologics strikes manufacturing and development deal with Kurma". BioProcess International.
  33. ^ Keenan, Joseph (7 February 2024). "Samsung Biologics, LegoChem partner to propel ADC development and production". Fierce Pharma.
  34. ^ "Samsung Biologics signs largest-ever $1.2 billion deal". Korea JoongAng. 2024.
  35. ^ "Samsung BioLogics no longer a holding company of Samsung Bioepis". The Korea Herald. 5 April 2019.
  36. ^ Angus Liu (28 January 2022). "Samsung buys Biogen out of biosimilar unit for $2.3B—not the whole Aduhelm headache". Fierce Pharma.
  37. ^ Biologics, Samsung. "Samsung Biologics completes spin-off to strengthen its focus as a pure-play CDMO". www.prnewswire.com. Retrieved 2025-12-03.
  38. ^ "Samsung's Life Science Fund invests in US biotech Jaguar Gene Therapy". KED Global. The Korea Economic Daily. 30 March 2022.
  39. ^ Jeong-yeo, Lim (5 August 2020). "Samsung Biologics launches S-CHOice cell line expression technology". The Korea Herald.
  40. ^ Byung-yeul, Baek (7 October 2022). "Samsung Biologics launches bispecific antibody platform S-DUAL". Korea Times.
  41. ^ Team, ADC Review | Editorial (2024-01-09). "Samsung Biologics Presents 2024 Business Plans » ADC Review". ADC Review. Retrieved 2025-12-03.
  42. ^ "Samsung Biologics Introduces Advanced Development Platforms to Boost Therapeutic Efficacy". biopharmaapac.com. Retrieved 2025-12-03.
  43. ^ Hae-yeon, Kim (2024-06-04). "[Bio USA] Samsung Biologics unveils new CDO platform". The Korea Herald. Retrieved 2025-12-03.
  44. ^ Team, ADC Review | Editorial (2024-01-09). "Samsung Biologics Presents 2024 Business Plans » ADC Review". ADC Review. Retrieved 2025-12-03.
  45. ^ "Samsung Biologics Introduces Advanced Development Platforms to Boost Therapeutic Efficacy". biopharmaapac.com. Retrieved 2025-12-03.
  46. ^ "Samsung Biologics Launches High-Concentration Formulation Platform". Contract Pharma. 2024-10-14. Retrieved 2025-12-03.
  47. ^ "Six Korean companies added to Dow Jones Sustainability World Index". The Korea Herald. 14 November 2021.
  48. ^ Eckford, Catherine. "2022 Terra Carta Seal: three pharma companies awarded". European Pharmaceutical Review.
  49. ^ Byung-yeul, Baek (13 February 2024). "Samsung Biologics recognized for response to climate change". The Korea Times.
  50. ^ Choi, Jasmine (23 January 2024). "Samsung Biologics Achieves Top 'Platinum' Rating in EcoVadis ESG Evaluation". Businesskorea. Business Korea.
  • Official website
  • Business data for Samsung Biologics:
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.